Articles related to SKIN CANCER

Discover how to navigate the evolving therapeutic landscape for advanced melanoma, with a focus on the latest immunotherapies, mitigation of treatment-associated adverse events, and patient-centric strategies to enhance shared decision-making and quality of life.

Cancer Therapy Advisor provides a variety of resources, including regimens used to supplement the most recent treatment strategies. Examine all regimens here.

In patients with stage IIIB-D or IV melanoma, adjuvant nivolumab with ipilimumab did not increase recurrence-free survival compared to nivolumab monotherapy. Both treatment regimens’ safety and health-related quality of life were similar with earlier research.

A 70-year-old woman with a skin lesion on her right temple is referred for assessment. She claims that the site originally came to light about a year ago and has grown in size ever since. An erythematous, fibrotic plaque with a depressed center is discovered during examination. What is the most likely cause of the lesion?

168 adults with unresectable stage IIIC-IV melanoma with progression after 1 line of systemic treatment (not including ipilimumab) were randomly assigned to receive tumor-infiltrating lymphocyte therapy or ipilimumab. With a median follow-up of nearly 3 years, the median PFS was 7.2 months in the TIL arm and 3.1 months in the ipilimumab arm.

As yet, there are no consensus treatment strategies for class 2 and 3 BRAF mutations. This systematic review and meta-analysis of published reports of patients with class 2 or 3 BRAF mutations from 2010 to 2021 assesses MAPK targeted therapy in the setting. The meta-analysis suggests that MAPK TTs have clinical activity in some class 2 and 3 BRAF-mutant cancers.